Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2026-01-14 M&A Activity
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
M&A Activity Classification · 95% confidence The document is a formal notice regarding the setting of a record date for shareholder rights in relation to a merger (small-scale merger) between SCM Lifescience and Poongjeon Pharmaceutical. It specifies the record date (2026-01-29) and the purpose (determining shareholders for dissenting rights). This type of regulatory disclosure regarding corporate actions and shareholder record dates is classified as a general regulatory filing.
2026-01-14 Korean
[기재정정]주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice regarding the convocation of an Extraordinary General Meeting (EGM) for SCM Lifescience. It details the agenda items, specifically the appointment of directors, and includes a correction notice for previously filed information. This type of document, which provides information to shareholders regarding upcoming meetings and voting items, is classified as a Proxy Solicitation & Information Statement (PSI).
2025-12-30 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) for SCM Lifescience Co., Ltd. It details the meeting date, location, agenda items (appointment of directors), and provides management information regarding board activities and business status. This document is a formal notice and information statement sent to shareholders to solicit votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2025-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically an amendment ('정정신고') to a previous filing. It details changes to stock option grants, including the cancellation of options for certain employees and updates to management information. This falls under the category of regulatory filings regarding capital structure and share-based compensation, which is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like DIRS (Director's Dealing) or SHA (Share Issue/Capital Change) perfectly, and is a formal regulatory disclosure.
2025-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically an amendment ('정정신고') to a previous filing. It details changes to the board of directors, management, and the status of stock option grants. Since this document pertains to corporate governance and regulatory reporting of stock-based compensation and management changes, and does not fit into specific categories like 'DEF 14A' (which is specific to US proxy statements) or 'DIRS' (which is for individual director trades), it falls under the general regulatory filing category.
2025-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details changes to stock option grants, including the cancellation of options due to employee departures and updates to management information. This type of filing, which concerns the issuance or modification of equity-based compensation instruments, falls under the category of share-related capital changes or regulatory disclosures regarding equity incentives. Given the specific nature of stock option grants and their amendments, it is classified as a Regulatory Filing (RNS) as it serves as a formal disclosure to the financial authorities.
2025-12-30 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.